Guobang Pharma Ltd. (SHA:605507)

Market Cap	11.39B
Revenue (ttm)	5.99B
Net Income (ttm)	797.84M
Shares Out	558.37M
EPS (ttm)	1.42
PE Ratio	14.36
Forward PE	12.17
Dividend	0.60 (2.96%)
Ex-Dividend Date	Jun 14, 2024

Volume	2,814,126
Average Volume	3,428,869
Open	20.25
Previous Close	20.25
Day's Range	20.25 - 20.52
52-Week Range	15.81 - 23.09
Beta	0.38
RSI	61.28
Earnings Date	Aug 15, 2025

About Guobang Pharma

Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives. It sells its products approximately in 110 countries and regions worldwide. Guobang Pharma Ltd. was founded in 1996 and is based in Xinchang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 4,003
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 605507

Financial Performance

In 2024, Guobang Pharma's revenue was 5.89 billion, an increase of 10.12% compared to the previous year's 5.35 billion. Earnings were 781.60 million, an increase of 27.61%.